Tag: SaNOtize

[PRESS RELEASE] Newly Published Phase 3 Study in People with COVID-19 Shows SaNOtize Nitric Oxide Nasal Spray Reduced Viral Load by 99% within Two Days

VANCOUVER, British Columbia & MUMBAI, July 13, 2022–SaNOtize Research & Development Corp., (“SaNOtize”), a Canadian anti-infective-focused therapeutics company, and Glenmark Pharmaceuticals Limited (“Glenmark”), a global, innovation-driven pharmaceutical company, today published results of a Phase 3 clinical trial in The Lancet Regional Health Southeast Asia, illustrating the effectiveness of nitric oxide nasal spray (NONS™) for the treatment of adult patients with COVID-19. Read more...

Read More

[SaNOtize in Business Wire] Clinical study suggests SaNOtize nitric oxide nasal spray is effective at preventing COVID-19 after high-risk exposure

VANCOUVER, British Columbia–(BUSINESS WIRE)–SaNOtize Research and Development (“SaNOtize”) today announced results from a retrospective clinical study assessing the efficacy of nitric oxide releasing nasal spray (NONS™) in preventing COVID-19 infection after high-risk exposure. Nitric oxide is a naturally occurring molecule known to have antimicrobial properties, including a direct effect on SARS-CoV-2 and its variants, the virus that causes COVID-19. The new study, conducted at Srinakharinwirot University in Bangkok, Thailand, found participants who took NONS after COVID-19 exposure were 75% less likely to become infected when compared to the control group, yielding a statistically significant reduction in infection rate. Read more...

Read More

Latest from Twitter